NYXH - Nyxoah S.A Average Forecast Price

This daily price chart for Nyxoah S.A. (NYXH) serves as an indicator for a business that combines the procurement of boards from contractors with final precision assembly, maintaining the premium value of Genio systems through reimbursement codes. The current figure is 3.31. Profitability growth is driven by scaling the production of microchips and electrodes, which significantly reduces costs as implant sales volumes increase.

NYXH (nyxoah.com) Analyst Consensus Forecast history from 07/04/2022 to 11/15/2026

Analytical breakdowns for Nyxoah SA (NYXH)

- stock price and consensus target price:

Share Price Nyxoah, S.A.|NYXH - Consensus Target

- market capitalization statistics:

Market Value Nyxoah|NYXH - Real Price to Acquire Entire Company

- shareholders' equity book value data:

Equity per Share Nyxoah S.A.|NYXH - Book Capitalization|Market Value to Book Value nyxoah.com|NYXH - Aggregate Company Assets

- business debt structure and liquidity details:

- net income and valuation multiples indicators:

NYXH - Net Profit|Projected Future Earnings Nyxoah S.A.|NYXH - Price to Earnings Ratio|Future Price to Earnings Nyxoah S.A.|NYXH - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Nyxoah S.A|NYXH - Operating profit EBITDA|Net earnings per share for the last four quarters Nyxoah S.A.|NYXH - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months nyxoah.com|NYXH - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Nyxoah S.A.

- issuer revenue and sales details:

NYXH - Company Sales|Company Projected Revenue Volume Nyxoah SA|NYXH - Price-to-Revenue Ratio|Forward Price to Sales Nyxoah|NYXH - Revenue Growth YoY (Last 12 Months)

General company analysis:Nyxoah (NYXH)

This indicator represents the arithmetic mean of the asset's target values, calculated by experts based on discounted cash flows and market capitalization. The consensus forecast price action for Nyxoah S.A. (NYXH) reflects market confidence in the commercial success of its patented hypoglossal nerve stimulator, where rising targets confirm the high value of the company's technological advantage in apnea therapy.

Competing companies